Jacobs Receives Contract From Biogen Idec, Inc. (Massachusetts) for Biotechnology Project in Denmark

PASADENA, Calif., May 15 /PRNewswire-FirstCall/ -- Jacobs Engineering Group Inc. announced today that they received a contract from Biogen Idec to provide engineering, procurement, validation, and site support services for the first cell culture manufacturing facility at the greenfield biotechnology plant in Hillerod, Denmark. The manufacturing facility is expected to produce TYSABRI(R) (natalizumab), which is used in the treatment of multiple sclerosis.

Officials did not disclose the contract details, but noted that the plant is scheduled to be completed in 2009.

Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. The company creates new standards of care in therapeutic areas with high unmet medical needs and has significant products serving patients in more than 90 countries. This will be their first manufacturing facility in Europe. Jacobs performed conceptual design for the facility and will execute this new scope of work from their office in Reading, England.

In making the announcement, Jacobs Group Vice President Phil Stassi said, "We are very enthusiastic about continuing our collaboration with Biogen Idec to help them bring this important drug treatment to market. This award strengthens our position as the leading engineering contractor for large European biotech projects."

Jacobs, with over 46,000 employees and revenues exceeding $8.0 billion, provides technical, professional, and construction services globally.

Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2006 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.

For additional information contact: Mary Bloom 626.578.6992 (Logo: http://www.newscom.com/cgi-bin/prnh/20051021/LAJACOBSEGLOGO )

CONTACT: Mary Bloom of Jacobs Engineering Group Inc., +1-626-578-6992

Web site: http://www.jacobs.com/